Developments, Evolution, and Implications of National Diagnostic Criteria for COVID-19 in China

Recently WHO has characterized COVID-19 as a pandemic. Diagnosing the disease accurately and decreasing misdiagnoses and missed diagnoses is very important for management. Therefore, we have analyzed the seven versions of China's national guidelines to examine how the diagnostic criteria roadmap has developed and evolved, in order to share our experience worldwide. In this article, we present the developments from the first to seventh versions, involving changes of case classification, changes to “suspected case,” changes in “confirmed case,” changes in clinical classifications, changes in “severe case,” and unchanged criteria. We have also discussed the reasons and implications for these changes and are looking forward to providing suggestions for worldwide understanding and management of this pandemic. A nucleic acid test is currently accepted as the gold standard method to confirm diagnosis. In addition, imaging examination and epidemiological history should also be considered as auxiliary diagnosis methods.

[1]  E. Lau,et al.  Effect of changing case definitions for COVID-19 on the epidemic curve and transmission parameters in mainland China: a modelling study , 2020, The Lancet Public Health.

[2]  Stephen D. Persell,et al.  Awareness, Attitudes, and Actions Related to COVID-19 Among Adults With Chronic Conditions at the Onset of the U.S. Outbreak , 2020, Annals of Internal Medicine.

[3]  R. Lu,et al.  Detection of SARS-CoV-2 in Different Types of Clinical Specimens. , 2020, JAMA.

[4]  Kwok-Hung Chan,et al.  Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens , 2020, Journal of Clinical Microbiology.

[5]  Dan Xu,et al.  Positive RT-PCR Test Results in Patients Recovered From COVID-19. , 2020, JAMA.

[6]  T. Phan,et al.  Genetic diversity and evolution of SARS-CoV-2 , 2020, Infection, Genetics and Evolution.

[7]  Yan Zhao,et al.  A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) , 2020, Military Medical Research.

[8]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[9]  P. Vollmar,et al.  Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany , 2020, The New England journal of medicine.

[10]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[11]  P. Horby,et al.  A novel coronavirus outbreak of global health concern , 2020, The Lancet.

[12]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  Colin A Graham,et al.  qSOFA is a Poor Predictor of Short-Term Mortality in All Patients: A Systematic Review of 410,000 Patients , 2019, Journal of clinical medicine.

[14]  M. Valenciano,et al.  2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1) pdm09 and B among elderly people in Europe: results from the I-MOVE plus project , 2017 .